Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
Joseph A. Fraietta(Parker Institute for Cancer Immunotherapy), Simon F. Lacey(Parker Institute for Cancer Immunotherapy), Elena J. Orlando(Novartis (United States)), Iulian Pruteanu-Malinici(Novartis (United States)), Mercy Gohil(University of Pennsylvania), Stefan Lundh(University of Pennsylvania), Alina C. Boesteanu(University of Pennsylvania), Yan Wang(University of Pennsylvania), Roddy S. O’Connor(University of Pennsylvania), Wei‐Ting Hwang(University of Pennsylvania), Edward Pequignot(University of Pennsylvania), David E Ambrose(University of Pennsylvania), Changfeng Zhang(University of Pennsylvania), Nicholas S. Wilcox(University of Pennsylvania), Felipe Bedoya(University of Pennsylvania), Corin L. Dorfmeier(University of Pennsylvania), Chen Fang(University of Pennsylvania), Lifeng Tian(University of Pennsylvania), Harit Parakandi(University of Pennsylvania), Minnal Gupta(University of Pennsylvania), Regina M. Young(University of Pennsylvania), F. Brad Johnson(University of Pennsylvania), Irina Kulikovskaya(University of Pennsylvania), Li Liu(University of Pennsylvania), Jun Xu(University of Pennsylvania), Sadik H. Kassim(Novartis (United States)), Megan M. Davis(University of Pennsylvania), Bruce L. Levine(University of Pennsylvania), Noelle V. Frey(University of Pennsylvania), Donald L. Siegel(University of Pennsylvania), Alexander C. Huang(Parker Institute for Cancer Immunotherapy), E. John Wherry(Parker Institute for Cancer Immunotherapy), Hans Bitter(Novartis (United States)), Jennifer L. Brogdon(Novartis (United States)), David L. Porter(University of Pennsylvania), Carl H. June(Parker Institute for Cancer Immunotherapy), J. Joseph Melenhorst(Parker Institute for Cancer Immunotherapy)
Cited by 1,751Open Access